if the pharma angle is all hogwash grass, you can kiss your shares goodby. no way Fuse generates the revs against mounting huge costs with the three products they have now. the only way would be for the three items to catch on and get re-ordered like crazy. I have seen nothing at anytime in the last two years that leads me to believe this will happen. I do not recall one time on this board when fast-rising costs were addressed in relationship to all these revs that we are supposed to get. The roll-out to Walgreen's will give a nice shot in the arm rev-wise, as will the second roll-out to the mystery client, but all the while, mounting costs will have to be more than offset by reorder revs and new customers. If we had the funds to accomplish all this, then maybe we could get to strong positive cash flow, but alas, we don't. Better hold out for pharma or a military contract.